All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-01-30T09:02:49.000Z

REGN1979 for relapsed/refractory B-cell non-Hodgkin lymphoma

Jan 30, 2020
Share:

Bookmark this article

REGN1979 is a bispecific antibody targeting CD20 and CD3 that is designed to cross-link and activate T-cells that express CD3 upon contact with CD20+ B-cells. This means tumor cells can be killed independently of T-cell receptor recognition. Rajat Bannerji, Rutgers Cancer Institute of New Jersey, New Jersey, US, presented updated results from the dose escalation phase of a first-in-human study of REGN1979, at the 61st American Society of Hematology (ASH) meeting in Florida, US. This article summarizes the updated results presented at the ASH meeting; these data may supersede the ones in the published abstract.1

Study design1

The dose escalation portion of the study enrolled patients with B-cell non-Hodgkin lymphoma (B-NHL), whilst the expansion cohorts will enroll patients with relapsed/refractory (R/R) aggressive lymphoma, and follicular lymphoma (FL) grade 1–3a following two prior lines of therapy.

The primary objectives of the study were to assess safety, tolerability, and dose-limiting toxicities (DLTs) of REGN1979. The secondary objectives were to evaluate anti-tumor activity, pharmacokinetics, and immunogenicity. Dosing of REGN1979 was in an escalating dose schedule using an (1) initial, (2) intermediate, and (3) step-up dose with the target dose achieved at the end of four weeks. REGN1979 was administered weekly by intravenous injection, followed by every two-weeks for a further 12 doses (total: 36 weeks).

Patient characteristics (N= 110)1

  • Median age: 67 years (range: 30–88)
  • 70% of patients were male
  • Most patients had stage III–IV disease by Ann Arbor (85.5%) and were diagnosed with diffuse large B-cell lymphoma (DLBCL, 55.5%) or FL (28.2%)
  • Median prior lines of therapy: 3 (range: 1–11)
  • 80% of patients were refractory to last treatment
  • Patients must have received a prior anti-CD20 therapy

At data cut-off on 3rd September 2019, 31 patients remained in the study (28.2%) with 69 discontinuing (62.7%), predominantly due to progression/recurrence of disease (n= 35) or death (n= 13). In total, 10 patients (9.1%) completed the study.

Safety1

The most common treatment-emergent adverse events (TEAEs) of any grade were pyrexia (80%) and cytokine release syndrome (CRS, 59.1%). Grade 3–4 TEAEs that occurred in 10% or more of patients are shown in Table 1 and were predominantly cytopenias. CRS grade ≥3 occurred in 6.4% of patients and no seizures or grade 4–5 neurologic events were observed.

Infections and infestations were reported in 50% of patients. Six patients discontinued due to TEAEs:

  • Grade 1: cytomegalovirus infection (n= 1)
  • Grade 3: hemolysis (n= 1), fatigue (n =1), pneumonia (n= 2), and toxoplasmosis (n= 1)

Six grade 5 TEAEs occurred during the study. Three deaths (due to cardiac arrest, multi-organ failure or acute renal failure) were considered unrelated to the study drug, whilst three deaths (due to gastric perforation, lung infection or pneumonia) were considered related to study treatment.

Table 1. TEAE grade 3–4 occurring in ≥10% of patients

TEAE, treatment-emergent adverse event

TEAE

n (N= 110)

%

Anemia

24

21.8

Hypophosphatemia

21

19.1

Neutropenia

21

19.1

Lymphopenia

21

19.1

Thrombocytopenia

15

13.6

Leukopenia

11

10.0

Infusion related reactions (IRRs) and CRS:

  • Most IRRs and CRS events happened during weeks 1–3 and subsequently declined
  • Grade 3 IRRs/CRS occurred in eight patients, with no grade 4 or 5 events reported
  • No patient discontinued study due to IRR or CRS

DLTs and MTD

  • No DLTs were observed during dose escalation
  • MTD was not reached

Efficacy1

Overall response rate (ORR), and rates of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) are given in Table 2, as of week 12.

In the FL cohort, 16/22 patients experienced complete metabolic response by PET scan. In the DLBCL cohort, the response rate was higher in patients who had not previously received chimeric antigen receptor (CAR) T-cell therapy. Survival rates and ongoing response rates are shown in Table 3 by diagnosis, dose of REGN1979, and prior CAR T therapy.

Table 2. Efficacy results by diagnosis and dose of REGN1979

CAR, chimeric antigen receptor; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease

Diagnosis

FL, n (%)

DLBCL, n (%)

DLBCL with prior CAR T therapy, n (%)

DLBCL without prior CAR T therapy, n (%)

Dose of REGN1979

≥5mg

≥80mg

≥80mg

≥80mg

N

22

19

12

7

ORR

21 (95.5)

11 (57.9)

6 (50.0)

5 (71.4)

CR

17 (77.3)

8 (42.1)

3 (25.0)

5 (71.4)

PR

4 (18.2)

3 (15.8)

3 (25.0)

0

SD

1 (4.5)

2 (10.5)

1 (8.3)

1 (14.3)

PD

0

3 (15.8)

2 (16.7)

1 (14.3)

Not available

0

3 (15.8)

3 (25.0)

0

Table 3. Median survival and responses by diagnosis, prior CAR T therapy and REGN1979 dosing

CAR, chimeric antigen receptor; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; NR, not reported; PFS, progression-free survival

 

Patients with FL

DLBCL with prior CAR T therapy

DLBCL without prior CAR T therapy

Dose of REGN1979

≥5mg

≥80mg

≥80mg

N

22

12

7

Median PFS, months (95% CI)

11.4

(6.7–not evaluable)

NR

NR

Median duration of follow-up, months (range)

6.8 (1.0–22.1)

2.6 (0.4–9.9)

5.3 (1.2–11.8)

Number of patients with ongoing response at last assessment

14/21

4/6

5/5

Number of patients with ongoing CRs at last tumor assessment

12/17

3/3

5/5

Conclusion1

REGN1979 was found to have an acceptable safety profile with no DLTs observed during the dose escalation phase of the trial. Most AEs were mild to moderate with no significant neurotoxicity reported. No patient discontinued due to IRR/CRS. Additionally, REGN1979 demonstrated clinical activity in heavily pre-treated patients with R/R B-NHL in a dose-dependent manner. 

At data cut-off, one patient in the expansion cohort experienced grade 5 tumor lysis syndrome and enrolment in the expansion cohort was subsequently halted whilst a safety amendment was made to the study protocol. A global multi-arm phase II trial (NCT03888105) evaluating REGN1979 in patients with R/R FL is also underway.2

Expert Opinion

  1. Bannerji R. et al., Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). Oral abstract #762. 61st American Society of Hematology (ASH) meeting & exposition, Florida, US
  2. Clinicaltrials.gov. Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma. https://clinicaltrials.gov/ct2/show/NCT03888105 [Accessed 2020 Jan 22]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 46 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox